Vertex Pharmaceuticals Inc

2026. g. 12. jūn. 19:36 UTC

Vertex Pharmaceuticals shares are higher today, reflecting stable trading conditions. The stock is positioned above its 20-day moving average, indicating positive market sentiment.

2026. g. 11. jūn. 23:56 UTC

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

2026. g. 10. jūn. 20:03 UTC

Vertex Pharmaceuticals shares are lower as inflation data aligns with forecasts. The stock continues to trade below its 20-day moving average.

2026. g. 9. jūn. 19:56 UTC

Vertex Pharmaceuticals shares are higher during Tuesday's session, having peaked earlier, though they have pulled back slightly. No specific news was identified for this movement.

2026. g. 8. jūn. 19:36 UTC

Vertex Pharmaceuticals shares are lower despite positive data on ALYFTREK for cystic fibrosis. The decline follows broader market dynamics after a strong U.S. jobs report.

2026. g. 5. jūn. 23:06 UTC

Vertex Pharmaceuticals shares are trading lower in after-market hours, with no specific news identified. Broader market conditions may be influencing the stock's movement.

2026. g. 4. jūn. 20:02 UTC

RBC reiterated its Outperform rating on Vertex Pharmaceuticals with a $543 price target, contributing to shares advancing despite an earlier pullback.

2026. g. 3. jūn. 23:06 UTC

Vertex Pharmaceuticals shares are trading higher in after-market hours. No specific news was identified to explain this movement amid broader market volatility.

2026. g. 2. jūn. 20:03 UTC

Vertex Pharmaceuticals' FDA acceptance of povetacicept application fails to lift shares, which are trading lower and below their 20-day moving average.

2026. g. 1. jūn. 19:41 UTC

Vertex Pharmaceuticals' Biologics License Application for povetacicept accepted by the FDA. Shares are lower today amid broader market sentiment despite this milestone.

2026. g. 29. maijs 22:06 UTC

Vertex Pharmaceuticals shares are higher in after-market hours, trading near the upper end of their one-month range and above their 20-day moving average.

2026. g. 28. maijs 20:02 UTC

Vertex Pharmaceuticals shares are higher today, continuing a steady upward trend since Wednesday. Broader market reactions to geopolitical tensions are influencing trading.

2026. g. 27. maijs 19:46 UTC

Truist Securities initiated coverage of Vertex Pharmaceuticals with a Buy rating and raised the price target to $542, contributing to today's price gain.

2026. g. 26. maijs 19:56 UTC

Vertex Pharmaceuticals shares are higher today, continuing recent upward momentum. No specific company news was identified to explain the price movement.

2026. g. 22. maijs 19:26 UTC

Vertex Pharmaceuticals shares are higher as Health Canada reviews suzetrigine, a new oral pain treatment. The stock shows modest gains since Thursday's close.

2026. g. 21. maijs 19:56 UTC

Vertex Pharmaceuticals shares rise as Health Canada reviews suzetrigine for acute pain treatment, marking a potential breakthrough in oral pain medication.

2026. g. 20. maijs 19:56 UTC

Vertex Pharmaceuticals is declining amid a presentation at the RBC Capital Markets Global Healthcare Conference, despite a generally positive analyst outlook for its pipeline.

2026. g. 19. maijs 23:26 UTC

Vertex Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains stable within its one-month trading range.

2026. g. 18. maijs 19:46 UTC

Vertex Pharmaceuticals shares are lower today, continuing a recent downward trend amid cautious investor sentiment and rising costs. No specific news was identified for the decline.

2026. g. 15. maijs 23:36 UTC

Vertex Pharmaceuticals shares are modestly higher in after-market hours. No specific news was identified to explain the movement.

2026. g. 14. maijs 19:16 UTC

Vertex Pharmaceuticals is declining today, having opened lower and reached a session low. Broader economic data may be influencing market concerns.

2026. g. 13. maijs 19:26 UTC

Vertex Pharmaceuticals is trading higher, maintaining gains since Tuesday amid market volatility and comments from Federal Reserve officials on inflation trends.

2026. g. 12. maijs 19:52 UTC

Vertex Pharmaceuticals reaches a five-week high amid strong market interest. Despite social media concerns over Journavx's effectiveness, the stock shows solid performance today.

2026. g. 11. maijs 19:16 UTC

Vertex Pharmaceuticals sees shares rise on strong cystic fibrosis growth. New therapies and expanded patient reach bolster positive revenue outlook, despite broader market fluctuations.

2026. g. 8. maijs 19:36 UTC

Vertex Pharmaceuticals trades higher today, despite no specific news. The stock remains 1.50% below its 20-day moving average, reflecting broader market weakness.

2026. g. 7. maijs 20:06 UTC

Vertex Pharmaceuticals faces stock decline despite CASGEVY's strong launch. The biotechnology sector downturn, including a drop in the iShares ETF, impacts its performance today.

2026. g. 6. maijs 19:56 UTC

Vertex Pharmaceuticals secures reimbursement for CASGEVY in Germany. This milestone enhances gene therapy access for severe sickle cell disease and beta thalassemia patients.

2026. g. 5. maijs 23:26 UTC

Vertex Pharmaceuticals Inc. sees slight after-hours decline. Trading below its 20-day moving average and near one-month low.

2026. g. 4. maijs 23:02 UTC

Vertex Pharmaceuticals faces pressure from biotech sector decline. Despite exceeding EPS estimates, revenue fell short, and halted VX-522 study dampens investor sentiment.